However, patients diagnosed with BRAFV600E-mutated thyroid cancers seldom benefit from PLX4032 due to the existence of MAPK/ERK as well as phosphatidylinositol 3-kinase/Protein Kinase B (PI3K/AKT) pathways feedback activation [15]. Here, AKT1 is linked to thyroid gland carcinoma.